

28 October 2026

ASX RELEASE

QUARTERLY ACTIVITIES AND CASH FLOW REPORTS – September 2026

Key Highlights from the Quarter

- The ACCENT trial in pancreatic cancer nears completion with promising data continuing to be recorded
- A collaboration with Eli Lilly, the world's largest pharmaceutical company, exploring narmafotinib in combination with Lilly's *KRAS* inhibitor olomorasib in non-Small Cell Lung Cancer was announced in August
- A publication detailing narmafotinib's activity in various preclinical pancreatic cancer models is now available online

Melbourne, Australia: Amplia Therapeutics Limited (ASX: ATX), ("Amplia" or the "Company"), a company developing new approaches for the treatment of cancer and fibrosis, is pleased to share further progress across its small molecule, focal adhesion kinase (FAK) inhibitor program and the release of its Appendix 4C Cash Flow Report (attached) for the quarter ending 30 September 2026.

Operations Update

The Company's primary focus continues to be the clinical development of its lead investigational drug narmafotinib. The mature data from the ACCENT trial, presented at the annual meeting of the American Association of Cancer Research, continues to generate interest from clinicians and scientists working in the field, as well as potential partners. Most notable of the data reported to date are the improvements in median progression free survival (mPFS) and median overall survival (mOS) of 2-3 months over chemotherapy alone; an overall response rate of 36% (42% when unconfirmed responses are included); and an unprecedented complete response rate of 7.8%, all without significant worsening of chemotherapy tolerability.

7.8%

**Complete
response rate**

Superior to chemo alone
(~0.2%)

5 CR's and 1 pCR from 64 pts

70%

**Disease
control rate**

Chemo alone -
50%

8% CR 28% PR 34% SD

11.1

months

**Median
overall survival**

Chemo alone -
8.5 mo

mPFS 7.7 mos, v5.5 mos,
(MPACT)

**No Extra
Burden**

**Safety &
tolerability**

Over chemo alone

Main narma TEAEs: nausea,
vomiting, diarrhoea

ABN 16 165 160 841


+61 (0) 3 9123 1140 | info@ampliatx.com

Level 5, 90 William Street, Melbourne VIC 3000 Australia

www.ampliatx.com

At the time of writing one patient remains on study after 19 months to date, whilst two (2) additional patients have completed 24 months on study and have moved onto treatment with narmafotinib under a special compassionate access scheme.


The Company is now in late-stage planning for the registrational study of narmafotinib and chemotherapy in pancreatic cancer. The first stage of this registrational trial, called ACCENT-MINI, will explore the safety, tolerability and pharmacokinetics of daily dosed narmafotinib in combination with gemcitabine and Abraxane chemotherapy, across 2-3 dose levels of narmafotinib. Three sites in Australia are proceeding with study start up activities, and ethics approval is expected imminently. Data from this trial will inform the doses to be taken into the next stage of the study with the final design to be agreed with the US FDA in a meeting planned for Q2 2027.



Registrational trial outline


(* Project Optimus: <https://www.fda.gov/about-fda/oncology-center-excellence/project-optimus>; PK -Pharmacokinetics; NDA = New Drug Application)

The Company is also building know-how and capability in the exciting new field of KRAS inhibitors and developing evidence to demonstrate narmafotinib can play a central role in helping these drugs fulfill their promise. The mutant protein KRAS, which occurs in various forms, is a critical driver in many cancers, most notably occurring in about 85% of pancreatic cancers, 30% non-Small Cell Lung Cancer (NSCLC) and 45% colorectal cancer. In recent years, drugs turning off the mutant KRAS protein have been developed with 3 drugs now approved by the FDA and over 80 other drugs in development around the world.



Unfortunately, the development of resistance to KRAS inhibitors significantly impacts their long-term effectiveness, and in some cases resistance is seen early in treatment (2-4 months). In March this year we presented data from preclinical studies showing that narmafotinib enhances the

activity of selected KRAS inhibitors, in models of pancreatic cancer and lung cancer, by blocking resistance mechanisms that develop within the cancer. **Our data**, which we continue to develop and expand upon, **shows that narmafotinib inhibits signalling processes that the cancer cells hijack to survive and proliferate even in the presence of KRAS inhibitors**. Recent data published by others, including the prestigious MD Anderson Cancer Center in the US, also support these findings [see bibliography].



Scan Me

In the Capan-1 KRAS^{G12V} pancreatic cancer xenograft model, mice with subcutaneous tumours were treated with narmafotinib and pan-RAS inhibitor daraxonrasib. The addition of narmafotinib enhanced the efficacy of daraxonrasib treatment, sustaining tumour growth inhibition once adaptive resistance to pan-RAS inhibition emerged and driving a deeper and more durable response.

In August this year the Company announced a collaboration and clinical trial supply agreement with Eli Lilly, the world's largest pharmaceutical company, to explore the combination of narmafotinib and Lilly's experimental KRAS inhibitor olomorasib. This exciting collaboration allows the Company to generate the first clinical evidence that narmafotinib can enhance the efficacy of a KRAS inhibitor. This study is focused on NSCLC given that olomorasib selectively inhibits the KRAS G12C mutation which is more prevalent in NSCLC than any other cancer. It is estimated that approx. 23,000 NSCLC patients with the G12C KRAS mutation will be diagnosed in 2026 in the US alone.

"Learnings from this study will be directly translatable to combinations of narmafotinib with other KRAS inhibitors in lung cancer as well as other cancers including pancreatic cancer. Importantly, from a commercial perspective, the relationship with Lilly, at this time, is non-exclusive, meaning that the Company is free to partner with other KRAS inhibitor developers if appropriate opportunities present themselves."

DR CHRIS BURNS

Amplia Tx CEO and MD

The Company continues to conduct preclinical research to explore new commercial opportunities and further develop our understanding of the mechanism of action and how this can inform patient selection and activity biomarkers. Our collaborators at the Garvan Institute, Sydney, led

by Prof. Paul Timpson, have recently published their studies of narmafotinib in preclinical pancreatic cancer models in the online science repository BioRxivⁱ. These studies extensively detail the activity of narmafotinib in decreasing tumour fibrosis and increasing immune reactivity in pancreatic cancer models, leading to improved responses when combined with chemotherapy.

Financial update

Amplia finished the September 2026 quarter with a cash position of \$20.8 million (June 2026: \$24.0 million). During the quarter, the Company had net operating cash outflows of \$3.1 million in relation to operating activities (June 2026: \$3.9 million outflows). Operating cashflows included:

- Outflows of \$1.2 million for staff and administration/corporate costs;
- Outflows of \$2.1 million for research and development costs, which primarily related to trial costs, Contract Research Organisation (CRO), manufacturing and other CMC related costs incurred in relation to the ACCENT Phase 2 clinical trial; and
- Inflows of \$0.2 million relating to interest income.

The Company also received its Research and Development Tax Incentive refund for the year ended 31 March 2026 of \$4.8m in October 2026, giving Amplia a \$25.6 million proforma cash balance on 30 September 2026.

Payments to Related Entities

In accordance with Listing Rule 4.7C, payments made to related parties and their associates included in item 6.1 of the Appendix 4C incorporates directors' fees, salaries and superannuation. Total payments made for the quarter equals \$157,500 and relate to payments to the CEO/Managing Director in line with the employment contract and payments to the Non-Executive Directors.

Bibliography

1. Focal Adhesion Kinase (FAK) Inhibition Synergizes with KRAS G12C Inhibitors in Treating Cancer through the Regulation of the FAK-YAP Signaling. [Adv. Sci. 2021, 2100250.](#)
2. Adaptive Feedback Signaling Through the FAK/SRC Pathway Promotes KRAS G12C Inhibitor Resistance [J. Thorac. Oncol. 2026, doi.org/10.1016/j.jtho.2026.103991](#)
3. Induced ERBB response and standing FAK dependency nominate separable KRAS-combination hypotheses in pancreatic cancer. [BioRxiv 2026, doi.org/10.64898/2026.07.09.737590v1](#)
4. EMT-associated focal adhesion signaling mediates resistance to RAS inhibition. [Cancer Res \(2026\) 86 \(18_Supplement_2\): PR008 doi.org/10.1158/1538-7445.PANCREATIC26-PR00](#)

- End -

For Further Information

Dr. Christopher Burns
CEO and Managing Director
Chris@ampliatx.com
www.ampliatx.com

ⁱ See <https://www.biorxiv.org/content/10.64898/2026.07.23.740234v1>

This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics.

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on [X](#) (@ampliatx) and [LinkedIn](#).

About Narmafotinib

Narmafotinib (AMP945) is the company's best-in-class inhibitor of the protein FAK, a protein over-expressed in pancreatic cancer and a drug target gaining increasing attention for its role in solid tumours. The drug, which is a highly potent and selective inhibitor of FAK, has shown promising data in a range of preclinical cancer studies. Narmafotinib is currently undergoing a clinical trial (the [ACCENT](#) trial) where it is dosed in combination with the chemotherapies gemcitabine and Abraxane in first-line patients with advanced pancreatic cancer. The trial has achieved its desired outcome in achieving a response rate of 36%, superior to chemotherapy alone, and a mOS of 11.1 months has been reported. A second trial – [_AMPLICITY](#) – is being run at sites in Australia investigating the combination of narmafotinib with the chemotherapy FOLFIRINOX in first-line patients with advanced pancreatic cancer.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

AMPLIA THERAPEUTICS LIMITED

ABN

16 165 160 841

Quarter ended ("current quarter")

30 September 2026

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (6 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	-	-
1.2 Payments for		
(a) research and development	(2,149)	(5,100)
(b) product manufacturing and operating costs	-	-
(c) advertising and marketing	-	-
(d) leased assets	-	-
(e) staff costs	(504)	(965)
(f) administration and corporate costs	(700)	(1,376)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	203	425
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	-
1.8 Other (bank guarantee and GST)	63	64
1.9 Net cash from / (used in) operating activities	(3,087)	(6,952)
2. Cash flows from investing activities		
2.1 Payments to acquire or for:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	(66)	(79)
(d) investments	-	-
(e) intellectual property	-	-
(f) other non-current assets	-	-

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (6 months) \$A'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (bank guarantee and security deposit)	-	-
2.6	Net cash from / (used in) investing activities	(66)	(79)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (repayment of lease liability)	(28)	(55)
3.10	Net cash from / (used in) financing activities	(28)	(55)

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	23,984	27,854
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(3,087)	(6,952)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(66)	(79)

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (6 months) \$A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(28)	(55)
4.5	Effect of movement in exchange rates on cash held	(30)	5
4.6	Cash and cash equivalents at end of period	20,773	20,773

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	2,737	2,386
5.2	Call deposits	18,036	21,598
5.3	Bank overdrafts	-	-
5.4	Other (provide details)		
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	20,773	23,984

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	157
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i>		

The amount at 6.1 includes Director fees and salary (including superannuation) for the CEO and Managing Director and Non-Executive Directors.

7.	Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i> <i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	Total financing facilities	-	-
7.5	Unused financing facilities available at quarter end		-
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		
	N/A		

8.	Estimated cash available for future operating activities	\$A'000
8.1	Net cash from / (used in) operating activities (item 1.9)	(3,087)
8.2	Cash and cash equivalents at quarter end (item 4.6)	20,773
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	20,773
8.5	Estimated quarters of funding available (item 8.4 divided by item 8.1)	6.7
	<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
	8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
	Answer: N/A	
	8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
	Answer: N/A	
	8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
	Answer: N/A	
	<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>	

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

28 October 2026

Date:

The Board of Directors

Authorised by:
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.